Numinus Wellness Inc. Announces First Quarter Fiscal 2025 Results
Numinus Wellness (OTCQB: NUMIF), a mental health care company specializing in psychedelic-assisted therapies, reported its Q1 2025 financial results. The company achieved significant revenue growth of 68.3%, reaching $2.01 million compared to $1.20 million in Q1 2024.
The company demonstrated improved operational efficiency with a gross profit margin increase to 49.3% from 38.6% year-over-year. Operating expenses decreased substantially by 51.1% to $2.07 million. The net loss narrowed to $1.29 million from $4.35 million in the prior year. As of November 30, 2024, Numinus maintained a cash position of $2.0 million.
Numinus Wellness (OTCQB: NUMIF), azienda specializzata nella cura della salute mentale e nelle terapie assistite con psichedelici, ha comunicato i risultati finanziari del primo trimestre 2025. La società ha registrato un crescita significativa dei ricavi del 68,3%, arrivando a $2.01 million rispetto a $1.20 million nel primo trimestre 2024.
L'azienda ha mostrato una maggiore efficienza operativa con un aumento del margine lordo al 49,3% rispetto al 38,6% anno su anno. Le spese operative sono diminuite sostanzialmente del 51,1%, attestandosi a $2.07 million. La perdita netta si è ridotta a $1.29 million dai $4.35 million dell'anno precedente. Al 30 novembre 2024, Numinus disponeva di una posizione di cassa pari a $2.0 million.
Numinus Wellness (OTCQB: NUMIF), una compañía de atención de salud mental especializada en terapias asistidas con psicodélicos, informó sus resultados financieros del primer trimestre de 2025. La empresa consiguió un crecimiento de ingresos significativo del 68,3%, alcanzando $2.01 million frente a $1.20 million en el 1T de 2024.
La compañía mostró una mayor eficiencia operativa con un aumento del margen bruto al 49,3% desde el 38,6% interanual. Los gastos operativos disminuyeron sustancialmente un 51,1% hasta $2.07 million. La pérdida neta se redujo a $1.29 million desde $4.35 million en el año anterior. Al 30 de noviembre de 2024, Numinus mantenía una posición de efectivo de $2.0 million.
Numinus Wellness (OTCQB: NUMIF)는 사이키델릭 보조 치료를 전문으로 하는 정신건강 관리 회사로서 2025년 1분기 실적을 발표했습니다. 회사는 매출이 68.3% 증가하여 $2.01 million을 기록했으며, 이는 2024년 1분기의 $1.20 million과 비교됩니다.
회사는 매출총이익률이 연간 기준 38.6%에서 49.3%로 상승하는 등 운영 효율성이 개선되었습니다. 영업비용은 51.1% 크게 줄어 $2.07 million가 되었고, 순손실은 전년의 $4.35 million에서 $1.29 million로 축소되었습니다. 2024년 11월 30일 기준 Numinus의 현금 보유액은 $2.0 million였습니다.
Numinus Wellness (OTCQB: NUMIF), une entreprise de santé mentale spécialisée dans les thérapies assistées par des psychédéliques, a publié ses résultats financiers du premier trimestre 2025. La société a enregistré une croissance significative des revenus de 68,3%, atteignant $2.01 million contre $1.20 million au 1T 2024.
L'entreprise a fait preuve d'une meilleure efficacité opérationnelle avec une hausse de la marge brute à 49,3% contre 38,6% d'une année sur l'autre. Les charges d'exploitation ont diminué sensiblement de 51,1% pour s'établir à $2.07 million. La perte nette s'est réduite à $1.29 million contre $4.35 million l'année précédente. Au 30 novembre 2024, Numinus disposait d'une trésorerie de $2.0 million.
Numinus Wellness (OTCQB: NUMIF), ein Unternehmen im Bereich psychische Gesundheit, das sich auf psychedelika-gestützte Therapien spezialisiert hat, meldete seine Finanzergebnisse für das erste Quartal 2025. Das Unternehmen erzielte ein erhebliches Umsatzwachstum von 68,3% und erreichte $2.01 million gegenüber $1.20 million im 1. Quartal 2024.
Das Unternehmen zeigte eine verbesserte operative Effizienz mit einer Steigerung der Bruttomarge auf 49,3% gegenüber 38,6% im Jahresvergleich. Die Betriebskosten sanken deutlich um 51,1% auf $2.07 million. Der Nettoverlust verringerte sich auf $1.29 million gegenüber $4.35 million im Vorjahr. Zum 30. November 2024 verfügte Numinus über eine Barposition von $2.0 million.
- None.
- Cash position remains relatively low at $2.0 million
- Company continues to operate at a loss despite improvements
All financial results are reported in Canadian dollars unless otherwise stated.
Vancouver, British Columbia--(Newsfile Corp. - August 8, 2025) - Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months ended November 30, 2024 ("Q1 2025").
Q1 2025 Performance Metrics
| For the quarter ended: | |||||||||
| Nov 30, 2024 (Q1 2025) | Nov 30, 2023 (Q1 2024) | % change | |||||||
| Total Revenue | $ | 2,013,779 | $ | 1,196,629 | |||||
| Cost of revenue | 992,622 | 734,686 | |||||||
| Gross Profit (Loss) | $ | 1,021,157 | $ | 461,943 | |||||
| Gross profit margin (loss) | 107 bps | ||||||||
| Operating expenses and other items | 2,065,596 | 4,226,850 | - | ||||||
| Loss and comprehensive loss | ( | ) | ( | ) | n/a | ||||
Balance Sheet and Liquidity
Numinus ended the quarter with cash and cash equivalents of
Numinus' unaudited condensed consolidated interim financial statements for the three months ended November 30, 2024, and related management's discussion and analysis are available on Numinus' Investor Relations website at www.investors.numinusnetwork.com and under the Company's profile on SEDAR+ at www.sedarplus.ca. These documents were prepared in accordance with IFRS.
About Numinus
Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model — including psychedelic research and clinic care — is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.
Learn more at www.numinusnetwork.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.
SOURCE: Numinus Wellness Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including, without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are "forward-looking statements". Forward-looking statements can be identified by the use of words such as "expects", "does not expect", "is expected", "believes", "intends", "anticipates", "does not anticipate", "believes" or variations of these words, expressions or statements, that certain actions, events or results "may", "could", "would", "might" or "will be" taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, ability of Numinus to maintain or increase earnings; ability of Numinus to achieve or maintain profitability; results of changes to operations from a financial or business perspective; the effect of cost containment measures on Numinus business and financial position; changes to cash burn rate, expenses, corporate programs or priorities, or unanticipated costs affecting cash runway or the pathway to positive cashflow or profitability, the effect of any transaction or other activity undertaken by the company in connection with the strategic review; interest in, uptake of and the ability to commercialize the Numinus Training; availability of subjects and trainers for experiential opportunities in practitioners training, if approved; dependence on obtaining and maintaining regulatory approvals, including the acquisition and renewal of federal, provincial, municipal, local or other licenses, and any inability to obtain all necessary government authorizations, licenses and permits to operate the Company's facilities; regulatory or policy changes such as changes in applicable laws and regulations, including federal, state and provincial legalization, if any, due to fluctuations in public opinion, industry perception of integrative mental health, including the use of psychedelic-assisted therapy, delays or inefficiencies or any other reason; any other factor or development likely to hamper the growth of the market; the Company's need for additional financing and the effects of financial market conditions and other factors on the availability of capital; competition, including that of more established and better funded competitors; the need to build and maintain alliances and partnerships, including with research and development companies, customers and suppliers; and other risk factors set forth in our annual information form dated July 25, 2025 and available on SEDAR+ at www.sedarplus.ca. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company's efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws.
For more information:
Investor Contact
Craig MacPhail
invest@numinusnetwork.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/261892
FAQ
What was Numinus Wellness (NUMIF) revenue in Q1 2025?
How much did Numinus (NUMIF) reduce its losses in Q1 2025?
What is Numinus Wellness's (NUMIF) cash position as of Q1 2025?
How did Numinus (NUMIF) improve its gross profit margin in Q1 2025?
What was the reduction in operating expenses for Numinus (NUMIF) in Q1 2025?
